Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Clinical Applications of Domperidone in Patients With Delayed Gastric Emptying

This study has been completed.
Information provided by (Responsible Party):
Jamie S. Barkin, M.D., Mt. Sinai Medical Center, Miami Identifier:
First received: April 29, 2013
Last updated: May 15, 2017
Last verified: May 2017
The purpose of the study is to treat patients with on-going slow stomach emptying(gastroesophageal reflux disease), who have failed to respond to standard therapy

Condition Intervention
Digestive System Disease
Other: Domperidone

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Supportive Care
Official Title: Clinical Applications of Domperidone in Patients With Refractory Gastroesophageal Reflux Disease or Delayed Gastric Solid-Phase Emptying

Resource links provided by NLM:

Further study details as provided by Jamie S. Barkin, M.D., Mt. Sinai Medical Center, Miami:

Primary Outcome Measures:
  • Clinical Applications of Domperidone in Patients with Refractory Gastroesophageal Reflux Disease (GERD)or Delayed Gastric Solid-Phase Emptying [ Time Frame: 5 years ]
    GERD or Delayed Gastric Emptying

Enrollment: 37
Study Start Date: December 2007
Study Completion Date: February 19, 2015
Primary Completion Date: February 19, 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Domperidone will be given at 10 mg before each meal and at bedtime. At completion of the study, patients will receive standard medical therapy
Other: Domperidone
Domperidone dosage may be increased depending on how well the patient responds. However before increasing the dosage, patients will have follow-up EKG to evaluate any possible side effects including irregular heartbeats.
Other Names:
  • Motilium
  • Motillium

Detailed Description:
This is a study on the effectiveness of domperidone, which increases movement through the digestive system for relief of symptoms, in patients who have delayed gastric solid-phase emptying

Ages Eligible for Study:   12 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Persistent esophagitis
  • Heartburn
  • Nausea
  • Vomiting
  • Severe dyspepsia
  • Severe chronic constipation

Exclusion Criteria:

  • History of, or current arrhythmias including ventricular tachycardia, - Ventricular fibrillation and Torsade des Pointes.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01844622

United States, Florida
Division of Gastroenterology, Mt. Sinai Medical Center
Miami Beach, Florida, United States, 33140
Mt. Sinai Medical Center, Division of Gastroenterology
Miami Beach, Florida, United States, 33140
Sponsors and Collaborators
Mt. Sinai Medical Center, Miami
Principal Investigator: Jamie S. Barkin, M.D. Mt. Sinai Medical Center
  More Information

Responsible Party: Jamie S. Barkin, M.D., Professor of Medicine, U of Miami and Chief, Div of GI, Mt. Sinai Med. Ctr, Mt. Sinai Medical Center, Miami Identifier: NCT01844622     History of Changes
Other Study ID Numbers: 07-39-H-08
Study First Received: April 29, 2013
Last Updated: May 15, 2017

Keywords provided by Jamie S. Barkin, M.D., Mt. Sinai Medical Center, Miami:
Digestive System Diseases Disease

Additional relevant MeSH terms:
Digestive System Diseases
Gastrointestinal Diseases
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Dopamine Antagonists
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action processed this record on May 25, 2017